ICUI vs. LRCX

Last updated Apr 1, 2026

Compare and contrast key facts about ICU Medical, Inc. (ICUI) and Lam Research Corporation (LRCX).

Performance

ICUI vs. LRCX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in ICU Medical, Inc. (ICUI) and Lam Research Corporation (LRCX). The values are adjusted to include any dividend payments, if applicable.

ICUI vs. LRCX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
ICUI ICU Medical, Inc.	-9.48%	-8.06%	55.57%	-36.66%	-33.65%	10.65%	14.63%	-18.51%	6.31%	46.59%
LRCX Lam Research Corporation	24.97%	139.16%	-6.84%	88.63%	-40.72%	53.66%	64.18%	119.33%	-24.40%	76.21%

Fundamentals

Market Cap ICUI : $3.19B LRCX : $270.39B
EPS ICUI : $0.28 LRCX : $4.89
PE Ratio ICUI : 469.34 LRCX : 43.69
PEG Ratio ICUI : 10.99 LRCX : 3.31
PS Ratio ICUI : 1.43 LRCX : 13.20
PB Ratio ICUI : 1.50 LRCX : 26.65
Total Revenue (TTM) ICUI : $2.23B LRCX : $20.56B
Gross Profit (TTM) ICUI : $822.04M LRCX : $10.24B
EBITDA (TTM) ICUI : $242.40M LRCX : $7.43B

Returns By Period

In the year-to-date period, ICUI achieves a -9.48% return, which is significantly lower than LRCX's 24.97% return. Over the past 10 years, ICUI has underperformed LRCX with an annualized return of 2.28%, while LRCX has yielded a comparatively higher 40.32% annualized return.

ICUI

• 1D: 3.01%
• 1M: -14.23%
• YTD: -9.48%
• 6M: 7.66%
• 1Y: -6.99%
• 3Y*: -7.83%
• 5Y*: -9.04%
• 10Y*: 2.28%

LRCX

• 1D: 6.87%
• 1M: -8.54%
• YTD: 24.97%
• 6M: 60.02%
• 1Y: 196.05%
• 3Y*: 60.68%
• 5Y*: 28.66%
• 10Y*: 40.32%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

ICUI vs. LRCX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ICUI

ICUI Risk / Return Rank: 32
ICUI Sharpe Ratio Rank: 34
ICUI Sortino Ratio Rank: 31
ICUI Omega Ratio Rank: 31
ICUI Calmar Ratio Rank: 33
ICUI Martin Ratio Rank: 32

LRCX

LRCX Risk / Return Rank: 97
LRCX Sharpe Ratio Rank: 98
LRCX Sortino Ratio Rank: 95
LRCX Omega Ratio Rank: 95
LRCX Calmar Ratio Rank: 98
LRCX Martin Ratio Rank: 99

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ICUI vs. LRCX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for ICU Medical, Inc. (ICUI) and Lam Research Corporation (LRCX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ICUI	LRCX	Difference
Sharpe ratio Return per unit of total volatility	-0.17	3.67	-3.84
Sortino ratio Return per unit of downside risk	0.04	3.58	-3.54
Omega ratio Gain probability vs. loss probability	1.01	1.50	-0.49
Calmar ratio Return relative to maximum drawdown	-0.28	9.82	-10.09
Martin ratio Return relative to average drawdown	-0.59	31.04	-31.63
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ICUI vs. LRCX - Sharpe Ratio Comparison

The current ICUI Sharpe Ratio is -0.17, which is lower than the LRCX Sharpe Ratio of 3.67. The chart below compares the historical Sharpe Ratios of ICUI and LRCX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	ICUI	LRCX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.17	3.67	-3.84
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.22	0.63	-0.86
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.06	0.92	-0.86
Sharpe Ratio (All Time) Calculated using the full available price history	0.23	0.41	-0.17

Correlation

The correlation between ICUI and LRCX is 0.23, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

ICUI vs. LRCX - Dividend Comparison

ICUI has not paid dividends to shareholders, while LRCX's dividend yield for the trailing twelve months is around 0.47%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
ICUI ICU Medical, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
LRCX Lam Research Corporation	0.47%	0.57%	1.19%	0.95%	1.53%	0.78%	1.04%	1.54%	2.79%	1.01%	1.28%	1.36%

Drawdowns

ICUI vs. LRCX - Drawdown Comparison

The maximum ICUI drawdown since its inception was -73.82%, smaller than the maximum LRCX drawdown of -87.90%. Use the drawdown chart below to compare losses from any high point for ICUI and LRCX.

Drawdown Indicators

	ICUI	LRCX	Difference
Max Drawdown Largest peak-to-trough decline	-73.82%	-87.90%	+14.08%
Max Drawdown (1Y) Largest decline over 1 year	-28.43%	-20.01%	-8.42%
Max Drawdown (5Y) Largest decline over 5 years	-68.82%	-56.39%	-12.43%
Max Drawdown (10Y) Largest decline over 10 years	-73.82%	-56.39%	-17.43%
Current Drawdown Current decline from peak	-58.31%	-14.26%	-44.05%
Average Drawdown Average peak-to-trough decline	-25.58%	-28.31%	+2.73%
Ulcer Index Depth and duration of drawdowns from previous peaks	13.32%	6.33%	+6.99%

Volatility

ICUI vs. LRCX - Volatility Comparison

The current volatility for ICU Medical, Inc. (ICUI) is 11.27%, while Lam Research Corporation (LRCX) has a volatility of 20.58%. This indicates that ICUI experiences smaller price fluctuations and is considered to be less risky than LRCX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ICUI	LRCX	Difference
Volatility (1M) Calculated over the trailing 1-month period	11.27%	20.58%	-9.31%
Volatility (6M) Calculated over the trailing 6-month period	24.62%	40.44%	-15.82%
Volatility (1Y) Calculated over the trailing 1-year period	41.33%	53.75%	-12.42%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	40.61%	45.53%	-4.92%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	37.30%	44.09%	-6.79%

Financials

ICUI vs. LRCX - Profitability Comparison

The chart below illustrates the profitability comparison between ICU Medical, Inc. and Lam Research Corporation over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

ICUI - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, ICU Medical, Inc. reported a gross profit of 202.99M and revenue of 540.70M. Therefore, the gross margin over that period was 37.5%.

LRCX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Lam Research Corporation reported a gross profit of 2.65B and revenue of 5.34B. Therefore, the gross margin over that period was 49.6%.

ICUI - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, ICU Medical, Inc. reported an operating income of 5.64M and revenue of 540.70M, resulting in an operating margin of 1.0%.

LRCX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Lam Research Corporation reported an operating income of 1.81B and revenue of 5.34B, resulting in an operating margin of 33.9%.

ICUI - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, ICU Medical, Inc. reported a net income of -9.67M and revenue of 540.70M, resulting in a net margin of -1.8%.

LRCX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Lam Research Corporation reported a net income of 1.59B and revenue of 5.34B, resulting in a net margin of 29.8%.